肺がんスクリーニング市場の2030年までの予測：がんタイプ別、診断タイプ別、年齢層別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、肺がんスクリーニングの世界市場は2023年に34億米ドルを占め、予測期間中にCAGR 10.1％で成長し、2030年には68億米ドルに達すると予測されています。

肺がんスクリーニングは、低線量コンピュータ断層撮影（LDCT）スキャンによって肺がんを早期に発見するための診断検査を含みます。ヘビースモーカーなどリスクの高い人に用いられます。早期発見によりタイムリーな介入が可能となり、治療成績が向上します。

米国臨床腫瘍学会（American Society of Clinical Oncology）によると、肺がんは女性で2番目に多いがんであり、男性は2020年に米国で235,000人以上の成人が罹患すると推定されています。

予防ヘルスケアに対する患者の需要の高まり

早期発見の利点に対する認識が高まるにつれ、患者は肺がんなどの潜在的な健康リスクを早期かつ治療可能な段階で発見するため、定期的な検診を含む予防措置を積極的に求めるようになっています。教育や意識向上キャンペーンに後押しされた積極的な健康管理へのパラダイムシフトは、予防医療重視の高まりと一致しています。個人の健康が優先され、予防ヘルスケア対策が選択されるにつれて、利用しやすく包括的な肺がんスクリーニングサービスに対する需要が高まり、検診プログラムの拡大と日常的なヘルスケアへの統合が推進されます。

偽陽性のリスク

検診プログラムは潜在的な症例を早期に発見することを目的としているが、偽陽性のリスクが内在しているため、不必要な不安、経過観察、侵襲的介入につながる可能性があります。偽陽性は、良性疾患やがんでない異常ががんの可能性があるとして検出されることから生じる可能性があり、患者の経験を複雑にし、精神的苦痛を引き起こす可能性があります。個人の精神的な負担だけでなく、偽陽性の場合、追跡検査や不必要な治療のためにさらなるヘルスケアコストと資源の利用を招く可能性があります。

政府の取り組みと資金援助

政府機関による支援政策と財政的支援は、スクリーニングプログラムの利用しやすさと手頃さを高め、普及を促進します。早期がん発見の社会的・経済的利益を認識するにつれて、政府は肺がんスクリーニングに対する認識と実施を促進する取り組みへの投資を増やしています。資金援助は、研究、技術の進歩、検診インフラの確立を促進することができます。公衆衛生機関、ヘルスケア提供者、および政策立案者間の協力的な取り組みは、効果的な検診プログラムの開発に貢献し、予防対策をより多くの人々が利用できるようにします。

放射線被曝の懸念

検診、特にコンピュータ断層撮影（CT）検査は、貴重な診断情報を提供する一方で、放射線による潜在的な健康リスクに対する懸念を引き起こします。電離放射線はがん発症リスクの増加と関連しているため、頻繁な検診による累積被曝は課題となっています。早期がん発見の利益と放射線被曝による害の可能性とのバランスを考慮することが重要です。このような懸念に対処するため、低線量CT検査の使用など、放射線量を最小限に抑える取り組みが進行中です。しかし、リスクは依然として検診プログラムへの参加を躊躇させ、肺がんスクリーニングの幅広い普及を妨げています。

COVID-19の影響：

COVID-19の流行は市場に大きな影響を与えました。ヘルスケアサービスの混乱、リソースの再配分、ウイルス感染への懸念により、定期検診は減少しています。検診や診断の遅れは、肺がんの発見を遅らせ、治療成績に影響を及ぼす可能性があります。さらに、COVID-19への対応に集中するあまり、予防ヘルスケアへの取り組みから関心と資源が遠ざかっています。医療制度がパンデミックの課題に適応していく中で、肺がんスクリーニングの取り組みを再開し優先順位をつけ、タイムリーで効果的な予防医療サービスの継続的な提供を確保する戦略が必要とされています。

予測期間中、X線部門が最大となる見込み

予測期間中、X線分野は市場規模が拡大し、費用対効果が高く、広く利用可能な診断ツールを提供すると予測されます。X線は、コンピュータ断層撮影（CT）スキャンほどの感度はないもの、初期スクリーニングにおいて重要な役割を果たしており、肺の異常の発見に役立っています。携帯型胸部X線は、特に高リスク集団において肺がんの早期徴候を発見するために一般的に使用されています。X線の導入が容易であることが、その普及に寄与し、日常的なスクリーニングと早期介入を容易にするため、肺がんスクリーニング・プログラムの全体的な有効性が高まる。

予測期間中にCAGRが最も高くなると予測されるのは病院分野です。

予測期間中、病院分野は有利な成長を遂げると予想されます。CTスキャンやX線などの高度な画像技術を備えた病院は、包括的で正確な肺がんスクリーニングを促進します。肺専門医や放射線専門医を含む集学的チームが、診断とその後のケアへの総合的なアプローチを保証します。病院は、リスク評価から結果の解釈まで検診を管理する上で重要な役割を果たし、フォローアップ・ケアと介入を調整する重要なポイントとしての役割を果たします。一元化されたヘルスケア機関である病院は、肺がんスクリーニングイニシアチブのアクセシビリティと有効性に大きく貢献しています。

最大のシェアを占める地域：

北米地域は、強固なヘルスケア・インフラ、予防医療に対する意識の高まり、肺がん有病率の高さなどを背景に、最大の市場シェアを占めると予想されます。確立された検診プログラムと先進医療技術が早期発見に貢献しています。政府の支援政策や医療機関の積極的な取り組みにより、検診サービスへのアクセスが向上しています。早期診断を重視するこの地域は、予防対策に対する患者の需要の高まりと相まって、北米を肺がんスクリーニングイニシアチブの最前線に位置づけ、技術革新を促進し、世界の肺がんスクリーニング市場の軌道を形成しています。

CAGRが最も高い地域：

予測期間中、アジア太平洋地域の急成長が予想されます。同地域の人口増加と肺がん有病率の増加は、検診サービスに対する需要を強調しています。政府の取り組みと先進医療技術の導入が市場の成長に寄与しています。中国やインドのような国々のヘルスケアシステムは早期発見を優先しているため、アジア太平洋地域の肺がんスクリーニング市場は、同地域における肺がんの負担増に対処するための積極的なアプローチを反映して、著しい開拓を目の当たりにしています。

無料のカスタマイズ提供：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレイヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• エンドユーザー分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の肺がんスクリーニング市場：がんタイプ別

• 非小細胞肺がん（NSCLC）
• 小細胞肺がん
• その他

第6章 世界の肺がんスクリーニング市場：診断タイプ別

• 低線量コンピュータ断層撮影（LDCT）
• X線
• その他

第7章 世界の肺がんスクリーニング市場：年齢層別

• 50未満
• 50歳以上

第8章 世界の肺がんスクリーニング市場：エンドユーザー別

• 病院
• 診断センター
• その他のエンドユーザー

第9章 世界の肺がんスクリーニング市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第11章 企業プロファイル

• FUJIFILM Holdings Corporation
• GE Healthcare
• Siemens Healthineers AG
• Canon Medical Systems Corporation
• Koninklijke Philips N.V.
• Medtronic
• Nuance Communications, Inc.
• PenRad Technologies, Inc.
• Volpara Solutions Limited.

List of Tables

• Table 1 Global Lung Cancer Screening Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
• Table 3 Global Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
• Table 4 Global Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
• Table 5 Global Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
• Table 6 Global Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
• Table 7 Global Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
• Table 8 Global Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
• Table 9 Global Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
• Table 10 Global Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
• Table 11 Global Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
• Table 12 Global Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
• Table 13 Global Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
• Table 14 Global Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 15 Global Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 16 Global Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 17 North America Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
• Table 18 North America Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
• Table 19 North America Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
• Table 20 North America Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
• Table 21 North America Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
• Table 22 North America Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
• Table 23 North America Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
• Table 24 North America Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
• Table 25 North America Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
• Table 26 North America Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
• Table 27 North America Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
• Table 28 North America Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
• Table 29 North America Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
• Table 30 North America Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 31 North America Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 32 North America Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 33 Europe Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
• Table 34 Europe Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
• Table 35 Europe Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
• Table 36 Europe Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
• Table 37 Europe Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
• Table 38 Europe Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
• Table 39 Europe Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
• Table 40 Europe Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
• Table 41 Europe Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
• Table 42 Europe Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
• Table 43 Europe Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
• Table 44 Europe Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
• Table 45 Europe Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
• Table 46 Europe Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 47 Europe Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 48 Europe Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 49 Asia Pacific Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
• Table 50 Asia Pacific Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
• Table 51 Asia Pacific Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
• Table 52 Asia Pacific Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
• Table 53 Asia Pacific Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
• Table 54 Asia Pacific Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
• Table 55 Asia Pacific Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
• Table 56 Asia Pacific Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
• Table 57 Asia Pacific Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
• Table 58 Asia Pacific Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
• Table 59 Asia Pacific Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
• Table 60 Asia Pacific Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
• Table 61 Asia Pacific Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
• Table 62 Asia Pacific Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 63 Asia Pacific Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 64 Asia Pacific Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 65 South America Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
• Table 66 South America Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
• Table 67 South America Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
• Table 68 South America Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
• Table 69 South America Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
• Table 70 South America Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
• Table 71 South America Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
• Table 72 South America Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
• Table 73 South America Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
• Table 74 South America Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
• Table 75 South America Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
• Table 76 South America Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
• Table 77 South America Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
• Table 78 South America Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 79 South America Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 80 South America Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)
• Table 81 Middle East & Africa Lung Cancer Screening Market Outlook, By Country (2021-2030) ($MN)
• Table 82 Middle East & Africa Lung Cancer Screening Market Outlook, By Cancer Type (2021-2030) ($MN)
• Table 83 Middle East & Africa Lung Cancer Screening Market Outlook, By Non-small Cell Lung Cancer (NSCLC) (2021-2030) ($MN)
• Table 84 Middle East & Africa Lung Cancer Screening Market Outlook, By Small Cell Lung Cancer (2021-2030) ($MN)
• Table 85 Middle East & Africa Lung Cancer Screening Market Outlook, By Other Cancer Types (2021-2030) ($MN)
• Table 86 Middle East & Africa Lung Cancer Screening Market Outlook, By Diagnosis Type (2021-2030) ($MN)
• Table 87 Middle East & Africa Lung Cancer Screening Market Outlook, By Low-dose computed tomography (LDCT) (2021-2030) ($MN)
• Table 88 Middle East & Africa Lung Cancer Screening Market Outlook, By X-ray (2021-2030) ($MN)
• Table 89 Middle East & Africa Lung Cancer Screening Market Outlook, By Other Diagnosis Types (2021-2030) ($MN)
• Table 90 Middle East & Africa Lung Cancer Screening Market Outlook, By Age Group (2021-2030) ($MN)
• Table 91 Middle East & Africa Lung Cancer Screening Market Outlook, By Below 50 (2021-2030) ($MN)
• Table 92 Middle East & Africa Lung Cancer Screening Market Outlook, By 50 and older (2021-2030) ($MN)
• Table 93 Middle East & Africa Lung Cancer Screening Market Outlook, By End User (2021-2030) ($MN)
• Table 94 Middle East & Africa Lung Cancer Screening Market Outlook, By Hospitals (2021-2030) ($MN)
• Table 95 Middle East & Africa Lung Cancer Screening Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
• Table 96 Middle East & Africa Lung Cancer Screening Market Outlook, By Other End Users (2021-2030) ($MN)

According to Stratistics MRC, the Global Lung Cancer Screening Market is accounted for $3.4 billion in 2023 and is expected to reach $6.8 billion by 2030 growing at a CAGR of 10.1% during the forecast period. Lung cancer screening involves diagnostic tests to detect lung cancer in its early stages, typically through low-dose computed tomography (LDCT) scans. It is used for individuals at high risk, such as heavy smokers. Early detection allows for timely intervention, improving treatment outcomes.

According to the American Society of Clinical Oncology (2020), lung cancer is the second most common cancer in women and men is estimated to affect over 235,000 adults in the U.S in the year 2020.

Market Dynamics:

Driver:

Rising patient demand for preventive healthcare

With a growing awareness of the benefits of early detection, patients are actively seeking preventive measures, including routine screenings, to detect potential health risks such as lung cancer at an early and more treatable stage. The paradigm shift towards proactive health management, fueled by education and awareness campaigns, aligns with the rising emphasis on preventive care. As individuals prioritize their well-being and opt for preventive healthcare measures, the demand for accessible and comprehensive lung cancer screening services rises, driving the expansion and integration of screening programs into routine healthcare practices.

Restraint:

Risk of false positives

While screening programs aim to detect potential cases early, the inherent risk of false positives can lead to unnecessary anxiety, follow-up procedures, and invasive interventions. False positives can result from benign conditions or non-cancerous anomalies being detected as potentially cancerous, complicating patient experiences and potentially causing psychological distress. Beyond the emotional toll on individuals, false positives can lead to additional healthcare costs and resource utilization for follow-up tests and unnecessary treatments.

Opportunity:

Government initiatives and funding

Supportive policies and financial backing from governmental bodies enhance the accessibility and affordability of screening programs, encouraging widespread adoption. As governments recognize the societal and economic benefits of early cancer detection, they are increasingly investing in initiatives that promote lung cancer screening awareness and implementation. Funding can facilitate research, technological advancements, and the establishment of screening infrastructure. Collaborative efforts between public health agencies, healthcare providers, and policymakers contribute to the development of effective screening programs, making preventive measures accessible to a broader population.

Threat:

Radiation exposure concerns

While screening, particularly through computed tomography (CT) scans, provides valuable diagnostic information, it raises apprehensions about potential radiation-induced health risks. The cumulative exposure from frequent screenings poses a challenge, as ionizing radiation is associated with an increased risk of cancer development. Balancing the benefits of early cancer detection with the potential harm from radiation exposure is a critical consideration. Efforts to minimize radiation doses, such as the use of low-dose CT scans, are underway to address these concerns. However, the perceived risk may still deter individuals from participating in screening programs, hindering the broader adoption of lung cancer screenings.

COVID-19 Impact:

The COVID-19 pandemic has impacted the market profoundly. Disruptions in healthcare services, reallocation of resources, and concerns about virus transmission have led to a decline in routine screenings. Delays in screening and diagnosis may result in the identification of lung cancer at later stages, affecting treatment outcomes. Additionally, the focus on COVID-19 response has redirected attention and resources away from preventive healthcare initiatives. As healthcare systems adapt to pandemic challenges, there is a need for strategies to resume and prioritize lung cancer screening efforts, ensuring the continued provision of timely and effective preventive healthcare services.

The x-ray segment is expected to be the largest during the forecast period

Over the projection period, it is predicted that the x-ray segment will experience a larger market size, providing a cost-effective and widely accessible diagnostic tool. While not as sensitive as computed tomography (CT) scans, X-rays play a crucial role in initial screenings, aiding in the detection of lung abnormalities. Portable chest X-rays are commonly used to identify early signs of lung cancer, particularly in high-risk populations. The ease of X-ray implementation contributes to its widespread adoption, facilitating routine screenings and early interventions, thus enhancing the overall effectiveness of lung cancer screening programs.

The hospitals segment is expected to have the highest CAGR during the forecast period

During the forecast period, it is expected that the hospitals segment will experience lucrative growth. Equipped with advanced imaging technologies such as CT scans and X-rays, hospitals facilitate comprehensive and accurate lung cancer screenings. Their multidisciplinary teams, including pulmonologists and radiologists, ensure a holistic approach to diagnosis and subsequent care. Hospitals play a crucial role in managing screenings, from risk assessment to result interpretation, and serve as key points for coordinating follow-up care and interventions. As centralized healthcare institutions, hospitals contribute significantly to the accessibility and effectiveness of lung cancer screening initiatives.

Region with largest share:

The North America region is expected to witness largest market share, driven by a robust healthcare infrastructure, increasing awareness of preventive healthcare, and a high prevalence of lung cancer. Well-established screening programs and advanced medical technologies contribute to early detection efforts. Supportive government policies and the proactive approach of healthcare organizations enhance accessibility to screening services. The region's emphasis on early diagnosis, coupled with a rising patient demand for preventive measures, positions North America at the forefront of lung cancer screening initiatives, fostering innovation and shaping the trajectory of the global lung cancer screening market.

Region with highest CAGR:

During the forecast period, a rapid growth rate is anticipated in the Asia-Pacific region. The region's expanding population, coupled with a growing prevalence of lung cancer, underscores the demand for screening services. Government initiatives, coupled with the adoption of advanced medical technologies, contribute to the market's growth. As healthcare systems in countries like China and India prioritize early detection, the lung cancer screening market in Asia Pacific is witnessing significant development, reflecting a proactive approach to address the increasing burden of lung cancer in the region.

Key players in the market:

Some of the key players in Lung Cancer Screening market include FUJIFILM Holdings Corporation, GE Healthcare, Siemens Healthineers AG, Canon Medical Systems Corporation, Koninklijke Philips N.V., Medtronic, Nuance Communications, Inc., PenRad Technologies, Inc. and Volpara Solutions Limited.

Key Developments:

In August 2022, PenRad, a company that develops software to increase efficiency for breast imaging and lung screening, was acquired by Intelerad, a major international provider of enterprise medical imaging solutions. The purchase broadens Intelerad's product lines for lung analytics and mammography, enabling radiologists, technicians, and other healthcare workers to work more efficiently and fulfill increased demand for cancer screening while enhancing patient care.

In April 2023, Centers for Medicare & Medicaid Services (CMS) released a national coverage determination (NCD) that broadens coverage for lung cancer screening with Low Dose Computed Tomography (LDCT), to enhance health outcomes for those who have lung cancer,. In the U.S., lung cancer is one of the most prevalent malignancies and main reason for cancer-related mortality in both men and women.

Cancer Types Covered:

• Non-small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer
• Other Cancer Types

Diagnosis Types Covered:

• Low-dose computed tomography (LDCT)
• X-ray
• Other Diagnosis Types

Age Groups Covered:

• Below 50
• 50 and older

End Users Covered:

• Hospitals
• Diagnostic Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Lung Cancer Screening Market, By Cancer Type

• 5.1 Introduction
• 5.2 Non-small Cell Lung Cancer (NSCLC)
• 5.3 Small Cell Lung Cancer
• 5.4 Other Cancer Types

6 Global Lung Cancer Screening Market, By Diagnosis Type

• 6.1 Introduction
• 6.2 Low-dose computed tomography (LDCT)
• 6.3 X-ray
• 6.4 Other Diagnosis Types

7 Global Lung Cancer Screening Market, By Age Group

• 7.1 Introduction
• 7.2 Below 50
• 7.3 50 and older

8 Global Lung Cancer Screening Market, By End User

• 8.1 Introduction
• 8.2 Hospitals
• 8.3 Diagnostic Centers
• 8.4 Other End Users

9 Global Lung Cancer Screening Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 FUJIFILM Holdings Corporation
• 11.2 GE Healthcare
• 11.3 Siemens Healthineers AG
• 11.4 Canon Medical Systems Corporation
• 11.5 Koninklijke Philips N.V.
• 11.6 Medtronic
• 11.7 Nuance Communications, Inc.
• 11.8 PenRad Technologies, Inc.
• 11.9 Volpara Solutions Limited.